ストックスクリーナーアプリを入手
187.39
4.44%
-8.6821
前日終値:
$196.07
開ける：
$195.5
24時間の取引高:
5.45M
Relative Volume:
0.76
時価総額：
$340.25B
収益：
$57.37B
当期純損益:
$4.20B
株価収益率:
79.74
EPS:
2.35
ネットキャッシュフロー:
$17.83B
1週間 パフォーマンス:
-3.18%
1か月 パフォーマンス:
+0.21%
6か月 パフォーマンス:
-6.88%
1年 パフォーマンス:
+15.14%
1日の値動き範囲:
$186.76
$195.82
1週間の範囲:
$186.76
$198.98
52週間の値動き範囲:
$153.58
$218.66
Abbvie Inc Stock (ABBV) Company Profile
ABBV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
187.41 | 340.25B | 57.37B | 4.20B | 17.83B | 2.35 |
|
LLY
Lilly Eli Co
|
775.32 | 737.81B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
154.91 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
66.37 | 277.97B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
111.16 | 222.45B | 53.22B | 12.86B | 14.85B | 6.39 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-05 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-04 | アップグレード | Argus | Hold → Buy |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-06-05 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-05-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-01-29 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-12-11 | アップグレード | Goldman | Neutral → Buy |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-30 | アップグレード | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-07-25 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-05 | ダウングレード | Argus | Buy → Hold |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2023-02-22 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-11-08 | ダウングレード | Societe Generale | Buy → Hold |
| 2022-08-01 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Underperform |
| 2022-05-06 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-02-28 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-03 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-03 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-03 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-03 | 繰り返されました | Goldman | Neutral |
| 2022-01-13 | 開始されました | Redburn | Buy |
| 2022-01-12 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-11-23 | アップグレード | Societe Generale | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2020-11-10 | 再開されました | Bernstein | Outperform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-23 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | アップグレード | Argus | Hold → Buy |
| 2020-05-18 | 再開されました | BofA/Merrill | Neutral |
| 2020-05-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 再開されました | Morgan Stanley | Overweight |
| 2020-04-20 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 繰り返されました | Cowen | Outperform |
| 2019-09-26 | アップグレード | Citigroup | Neutral → Buy |
| 2019-08-20 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 開始されました | Goldman | Neutral |
| 2019-04-29 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
すべてを表示
Abbvie Inc (ABBV) 最新ニュース
AbbVie to Present at the Bank of America Securities Healthcare C - GuruFocus
JNJ vs. ABBV: Which Pharma Powerhouse Has Better Growth Prospects? - TradingView
AbbVie (ABBV) Set for Gains with Medicare Policy Shift | ABBV St - GuruFocus
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. LawsuitABBV - marketscreener.com
ChatGPT Stock Advice: AbbVie Inc. (ABBV) Among Top Stock Recommendations - Yahoo Finance
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - GlobeNewswire Inc.
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for InvestorsContact The Gross Law Firm - marketscreener.com
AbbVie Inc. (ABBV) Stock Analysis: Navigating Growth with a 6.15% Upside Potential - DirectorsTalk Interviews
Viral Conjunctivitis Drugs Market Overall Study Report - openPR.com
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash? - Yahoo Finance
Invest in These ETFs to Prepare Your Portfolio for a Recession - The Motley Fool
Allergan Aesthetics Boosts Women Entrepreneurs with BOTOX Cosmetic Initiative (ABBV) - GuruFocus
Fund Update: SATURNA CAPITAL CORP added 40,521 shares of ABBVIE ($ABBV) to their portfolio - Nasdaq
CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TradingView
Shareholders of Cerevel Therapeutics Holdings, Inc. Should Conta - GuruFocus
Shareholders of Cerevel Therapeutics Holdings, Inc. Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your RightsABBV - marketscreener.com
BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project" - AbbVie News Center
AbbVie shares snap seven-session gaining streak - MSN
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV)June 3, 2025 Deadline to Join – Contact The Gross Law Firm - TradingView
June 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ABBV - marketscreener.com
PTAB Axes AbbVie Unit's Cancer Drug Patent As Invalid - Law360
Androgen Drugs Market Detailed in New Research Report By 2032 | AbbVie Inc.,Endo International plc - openPR.com
FDA approves AbbVie’s upadacitinib for giant cell arteritis - Yahoo Finance
AbbVie secures FDA approval for Rinvoq to treat giant cell arteritis - World Pharmaceutical Frontiers
In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis - insights.citeline.com
AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type Of Arthritis - Benzinga
Why AbbVie Stock Topped the Market Today - MSN
AbbVie (NYSE:ABBV) Receives FDA Approval For RINVOQ In Treating Giant Cell Arteritis - Yahoo Finance
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - Benzinga
Stock Of The Day: AbbVie's Rally Looks Stretched — Could A Reversal Be Next? - Benzinga
AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data - Endpoints News
AbbVie Says Rinvoq Medication Gets FDA Approval to Treat Giant Cell Arteritis - marketscreener.com
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
AbbVie (ABBV) Target Price Increased Following Strong Quarterly Results | ABBV Stock News - GuruFocus
FDA Approval for AbbVie's Rinvoq (ABBV) in Treating Giant Cell A - GuruFocus
RINVOQ® Receives U.S. FDA Approval for Giant Cell Arteritis - Investing News Network
Guggenheim Adjusts AbbVie Price Target to $216 From $214, Maintains Buy Rating - marketscreener.com
Morgan Stanley Boosts AbbVie (ABBV) Price Target to $250 | ABBV Stock News - GuruFocus
Why AbbVie Stock Trounced the Market Today - MSN
AbbVie (ABBV) Stock Rises on Positive Analyst Notes - GuruFocus
Maybe In May: US FDA Calls Coming On Moderna Next-Gen COVID-19 Vaccine, AbbVie’s Big ADC Bet - insights.citeline.com
S&P 500 Gains and Losses Today: AbbVie Stock Advances After Beat-and-Raise Earnings Report - Investopedia
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst - Benzinga
AbbVie (ABBV) Target Price Raised as Confidence Grows in Long-Te - GuruFocus
AbbVie (ABBV) Sees Price Target Boost from BofA | ABBV Stock New - GuruFocus
AbbVie Stock Rises. Earnings Beat, Guidance Raised But Trump Tariffs May Bite. - Barron's
HSBC Adjusts Price Target for AbbVie (ABBV) Amid Potential Tarif - GuruFocus
AbbVie Lifts Profit Guidance as Newer Drugs Drive Sales Beat - MSN
HSBC Adjusts Price Target on AbbVie to $205 From $230, Maintains Buy Rating - marketscreener.com
AbbVie makes its tariffs-driven investment play - Pharmaphorum
Abbvie Inc (ABBV) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
大文字化:
|
ボリューム (24 時間):